ProCE Banner Activity

All Eyes on ExPEC: A Major Driver of Invasive Disease and Antimicrobial Resistance

Podcast Episodes
Listen to expert insights on key concepts of ExPEC, including virulence factors associated with invasive disease, antimicrobial resistance profiles observed in clinical practice, populations at risk for invasive disease, and the current landscape of vaccine development.

Released: October 19, 2022

Expiration: October 18, 2023

Share

Faculty

Lilian Abbo

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Julie Ann Justo

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

David Van Duin

David Van Duin, MD, PhD, FIDSA, FAST

Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Therapeutics Division of Janssen Products

Program Director Disclosure

Program Director

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Lilian Abbo, MD, FIDSA: consultant/advisor/speaker: Ferring.

Faculty Disclosure

Primary Author

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Julie Ann Justo, PharmD, MS: consultant/advisor/speaker: bioMérieux, Entasis Therapeutics, Gilead Sciences, Merck, Shionogi, Spero Therapeutics, Therapeutic Research Center; individual publicly traded stock/stock options: Vaxart.

David Van Duin, MD, PhD, FIDSA, FAST

Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

David Van Duin, MD, PhD, FIDSA, FAST: consultant/advisor/speaker: Entasis, Merck, Pfizer, Qpex, Roche, Shionogi, Union; researcher: Merck, Shionogi.